Aug 20, 2026 08:00AM
Aug 20, 2026 08:00AM
Aug 18, 2026 08:01AM
Aug 18, 2026 08:00AM
Aug 4, 2026 08:01AM
Aug 4, 2026 08:00AM
Apr 7, 2026 08:00AM Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Mar 26, 2026 08:02AM
Mar 26, 2026 08:00AM
Mar 16, 2026 08:02AM
Mar 16, 2026 08:00AM
Nov 19, 2025 08:01AM
Nov 19, 2025 08:00AM
Jul 28, 2025 08:00AM Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Jul 23, 2025 08:00AM
Jun 16, 2025 08:00AM
May 29, 2025 08:04AM
May 29, 2025 08:00AM
May 19, 2025 08:03AM
May 19, 2025 08:00AM
May 13, 2025 08:00AM Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 8, 2025 08:01AM
May 8, 2025 08:00AM
May 7, 2025 08:00AM
Mar 25, 2025 08:00AM
Mar 18, 2025 08:00AM
Mar 11, 2025 08:00AM
Mar 4, 2025 08:11AM Alzamend Neuro (ALZN) Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Mar 4, 2025 08:10AM
Feb 25, 2025 08:00AM
Feb 19, 2025 08:04AM
Feb 19, 2025 08:00AM
Jan 15, 2025 08:00AM
Dec 18, 2024 08:00AM
Dec 12, 2024 08:00AM Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Nov 19, 2024 08:02AM
Nov 19, 2024 08:00AM
Oct 16, 2024 08:06AM
Oct 16, 2024 08:00AM
Oct 15, 2024 08:04AM
Oct 15, 2024 08:00AM
Oct 10, 2024 08:00AM Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Aug 26, 2024 08:04AM
Aug 26, 2024 08:00AM
Aug 19, 2024 08:06AM
Aug 19, 2024 08:00AM
Aug 12, 2024 08:03AM
Aug 12, 2024 08:00AM
Aug 6, 2024 08:00AM Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Aug 5, 2024 09:10AM

1,223,229 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All